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Hyperlipidemia is associated with increased risk of the development of cardiovascular diseases. Although
a great deal of attention has been paid to the hypolipidemic activity of fucoidan, complex polysaccharides
from brown seaweeds, the underlying mechanism is still unclear. This study was performed to investi-
gate whether and how fucoidan has lipid-lowering potential in poloxamer-407 (P407)-induced hyper-
lipidemic mice. Fucoidan treatment 2 h after acute administration of P407 in these mice signiﬁcantly
reduced serum total cholesterol, triglycerides, and LDL cholesterol levels, but increased the levels of HDL
cholesterol. In HepG2 hepatocytes and the liver, fucoidan decreased the expression of FAS and ACC mRNA
with no or only a moderate inhibitory effect on SREBP-1c mRNA expression. Furthermore, fucoidan
attenuated the hepatic expression of mature SREBP-2 protein with a subsequent decrease in hepatic
HMG-CoA reductase mRNA expression and an increase in hepatic LDL receptor mRNA expression. In
addition, atherosclerotic lesions in the aorta of chronically P407-treated mice were also reduced by
fucoidan. These ﬁndings indicate that fucoidan improves serum lipid levels by regulating the expression
of key enzymes of cholesterol and triglyceride syntheses in the liver through modulation of SREBP-2.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Hyperlipidemia, in which the levels of any or all lipids and/or
lipoproteins are abnormally elevated in the blood, contributes to
the development of atherosclerosis and related cardiovascular
diseases, which are the primary leading causes of death worldwide
(1). For example, the recent study indicated that one of the most
strongly predictive cardiovascular risk factors for myocardial
infarction is dyslipidemia characterized by elevated concentrations
of serum triglyceride (TG) as well as increased levels of low-density
lipoprotein cholesterol (LDL-c) and decreased levels of high-density
lipoprotein cholesterol (HDL-c) (2,3). Therefore, any rational stra-
tegies for prevention and treatment of atherosclerosis as well as
reduction of the incidence of related cardiovascular diseases shouldan Science Research Center,
e University, Hoegi-dong,
ea. Tel.: þ82 2 961 0366;
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).be closely associated with targeting hyperlipidemia by drugs and/
or dietary intervention.
The liver plays a central role in themaintenance of systemic lipid
homeostasis through regulating several lipid metabolic pathways,
such as lipogenesis and lipoproteinuptakeand secretion in response
to nutritional and hormonal signals (4). However, dysregulation of
lipidmetabolism in the liver results inhyperlipidemia, characterized
by an excess of lipids, such as total cholesterol (TC), TG, and oxidized
LDL, and a lackofHDL in the bloodstream. Recently, sterol regulatory
element-binding proteins (SREBPs) have attracted a great deal of
attention as important transcription factors involved in the regula-
tionof lipidmetabolismandhomeostasis in the liver, inducingmany
genes involved in lipid synthesis and the uptake of lipoproteins (5).
There are three SREBP isoforms, SREBP-1a, SREBP-1c, and SREBP-2,
encoded by two genes, SREBP1 and SREBP2, which have different
roles in lipid metabolism (6); SREBP-1c plays an essential role in TG
and fatty acid syntheses by regulating the expression of lipogenic
genes, including acetyl-CoA carboxylase (ACC) and fatty acid syn-
thase (FAS) (7), whereas SREBP-2 is relatively speciﬁc to cholesterol
synthesis by regulating the expression of genes involved in choles-
terol synthesis and uptake, such as 3-hydroxy-3-methylglutaryl-
CoA reductase (HMGCR) and LDL receptor (LDLR) (7,8).When excessnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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(SCAP),which contains a cholesterol-sensing domain, SCAP strongly
interacts with a retention protein (Insig-1 or -2), tethering the
SREBPeSCAP complex in the endoplasmic reticulum. When
cholesterol levels are low, the SREBPeSCAP complex is transported
to the Golgi where it is processed by two proteases (site-1 protease
and site-2 protease) into the mature form (6). Therefore, release of
SREBPeSCAP complex from the ER is the critical point in feedback
regulation of cholesterol metabolism.
Marine natural products, especially polysaccharides from ma-
rine resources, have attracted increasing attention due to their
various biological activities (9). Fucoidan, a sulfated polysaccharide
with a fucose backbone found mainly in marine brown algae (10),
also has various biological activities, such as antioxidation (11),
anticoagulation (12), antitumor (13), inhibition of lipid accumula-
tion (14), and anti-inﬂammatory effects (15). The potential lipid-
lowering property of fucoidan was reported previously in several
studies. Administration of fucoidan from Laminaria japonica (family
Laminariaceae) decreased serum TC, TG, and LDL-c concentrations,
while increasing HDL-c levels, in a high-fat emulsion-fed hyper-
lipidemic rat model (16). Fucoidan from Cladosiphon okamuranus
(family Chordariaceae) also reduced the isoproterenol-induced in-
creases in concentrations of TC, TG, and LDL-c but increased that of
HDL-c in a rat model of myocardial infarction (17). These beneﬁts of
fucoidan may have been mediated by inhibition of lipid accumu-
lation and stimulation of lipolysis (14). However, it remains unclear
whether and how fucoidan exerts hypolipidemic effects.
The present study was performed to investigate whether and
how fucoidan affects lipid metabolism in P407-induced hyper-
lipidemic mice and human hepatoma HepG2 cells. In addition, the
hypolipidemic effect of fucoidan and its hepatic regulation of lipid
synthesis were investigated. The antiatherogenic effect of fucoidan
was also examined in the atherosclerotic mouse aorta.
2. Materials and methods
2.1. Chemicals and reagents
Fucoidan from Fucus vesiculosus (family Fucaceae) was purchased
from SigmaeAldrich (St. Louis, MO, USA). Poloxamer-407 was ob-
tained from BASF Co. (Parsippany, NJ, USA). Minimum essential me-
dium (MEM), fetal bovine serum (FBS), penicillin/streptomycin, and
phosphate-buffered saline (PBS) were purchased from WelGENE
(Seoul, Korea).AnEZ-Cytoxcell viabilityassaykitwaspurchased from
Daeil Lab (Seoul, Korea). TRIzol reagent was purchased from Life
Technologies (Carlsbad, CA, USA). Reverse transcriptase and Taq po-
lymerasewere purchased from Takara Bio (Shiga, Japan). The nucleic
acid dye GelRed was purchased from Biotium Inc. (Hayward, CA,
USA). Goat anti-human HMGCR, goat anti-mouse LDLR and rabbit
anti-humanSREBP-2were purchased fromSantaCruzBiotechnology
(Santa Cruz, CA, USA). Mouse anti-human b-actin was purchased
from SigmaeAldrich (St. Louis, MO, USA). Horseradish peroxidase
(HRP)-conjugatedgoat anti-rabbit goat anti-mouse, anddonkeyanti-
goat secondary antibodies were obtained from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Oligonucleotides used as primers for
PCR were synthesized by COSMO Genetech (Seoul, Korea).
Commercially available diagnostic kits for cholesterol, TG and HDL-c
were purchased from Bio Clinical System Co. (Anyang, Korea). All
other chemicals and reagents not speciﬁcally cited here were pur-
chased from SigmaeAldrich.
2.2. Cell culture
HepG2, a human hepatoma cell line, was obtained from the
Korean Cell Line Bank (Seoul, Korea). The cells were grown in MEMsupplemented with 10% heat-inactivated FBS, penicillin (100 U/ml),
and streptomycin (100 mg/ml) mixture, and 25 mM HEPES at 37 C
in a humidiﬁed incubator with 5% CO2. To upregulate the mevalo-
nate pathway, the cells were incubated in medium containing LPDS
(18). For the experiments, HepG2 cells were plated in 10% FBS-
DMEM and incubated for 24 h. Thereafter, all cells were treated
with 10% LPDS-MEM with or without the indicated concentrations
of fucoidan for 24 h.
2.3. Animals
Adult male C57BL/6NTacSam mice (7 weeks old) were obtained
from Samtako (Yongin, Korea). The animals were acclimatized to
the laboratory environment for 1 week before starting the experi-
ments. All mice were maintained on a 12-h lightedark cycle with
free access to food and water. The experimental procedures were
approved by the Kyung Hee University Institutional Animal Care
and Use Committee.
2.4. Cytotoxicity assay
Cytotoxicity was assessed by WST assay using the EZ-Cytox cell
viability assay kit (Daeil Lab) according to the manufacturer's in-
structions. Brieﬂy, HepG2 cells were treated with various concen-
trations of fucoidan (up to 500 mg/ml). Twenty-four hours later,
10 ml kit reagentwas added into eachwell. After 2 h, the plates were
read at 450 nm using a microplate reader (Molecular Devices,
Sunnyvale, CA, USA). The results are expressed as percentages of
untreated controls.
2.5. Schedules for poloxamer-407-induced hyperlipidemia,
fucoidan treatment, and sampling
Aqueous P407 solutions were prepared according to the cold
method (19). Brieﬂy, P407 was mixed with cold saline and stored
overnight at 4 C to facilitate dissolution of P407. As shown in Fig.1A,
for the acute studies, mice were fasted overnight prior to P407 in-
jection and then injected intraperitoneally with a single 250 mg/kg
dose of P407 followed by another 6-h fast. Control animals received
the same volume of cold sterile saline as vehicle. Animals were
randomly divided into six experimental groups (n ¼ 6 each): NOR,
normal mice treated with saline; P407, P407-induced hyper-
lipidemic mice treated with saline; FCN10, P407-induced hyper-
lipidemic mice treated with 10 mg/kg fucoidan; FCN30, P407-
induced hyperlipidemic mice treated with 30 mg/kg fucoidan;
FCN50, P407-induced hyperlipidemic mice treated with 50 mg/kg
fucoidan; STA, P407-induced hyperlipidemic mice treated with
10 mg/kg atorvastatin. Fucoidanwas dissolved in normal saline just
before use and administered intraperitoneally tomice 2 h after P407
administration. As a positive control, atorvastatin was used instead
of fucoidan (STA group). Blood samples were collected 24 h after
P407 injection. To examine the effects of fucoidan on P407-induced
atherogenesis,micewere injected intraperitoneallywith 400mg/kg
P407 every third day for 16weeks (Fig.1B). Fucoidan (50mg/kg) and
atorvastatin (10 mg/kg) were only administered intraperitoneally
2 h after each P407 injection. Aortas were collected 24 h following
the ﬁnal injection of P407.
2.6. Determination of serum lipid levels and the atherogenic index
Twenty-four hours after P407 injection, blood was collected
through cardiac puncture, and the serumwas separated. Before blood
sampling, micewere fasted for 8 h. Serum levels of TC, TG, and HDL-c
were measured using commercial kits according to the manufac-
turer's instructions. LDL-cwascalculatedusing theequationLDL¼TC/
Fig. 1. Schematic diagram of the experimental procedure to develop an acute hyperlipidemic model (A) and a chronic atherosclerosis model (B) using P407 in mice. Solid
arrows in (B) indicate the time points for intraperitoneal injection of P407 and fucoidan.
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atherogenic index (AI) was calculated as (TC HDL-c)/HDL-c (21).2.7. Quantiﬁcation of aortic intima-media thickness
Formalin-ﬁxed, parafﬁn-embedded sections of thoracic aortas
were stained with hematoxylin and eosin (HeE). Quantiﬁcation of
the maximal intimal thickness was then accomplished by deter-
mining the maximal intima-media thickness deﬁned as the
maximal measurement from the lesion luminal surface to the outer
surface of the vessel wall using DP2-BSW software (Olympus Ltd.,
Tokyo, Japan) at 400 magniﬁcation. Three measurements of
intima-media thickness were taken at the site of the greatestTable 1
List of primers used for PCR ampliﬁcation.
Gene name Sequence (50 / 30)
For mouse tissues
SREBP-1c Forward TGGACGAGCTGGCCTTCGGT
Reverse GGCCAGCGGCAGGCTAGATG
FAS Forward CGCACCGGCTACCAAGCCAA
Reverse CACGCATGGGCAGCACCAGA
ACC Forward CCCAGAGGTTCCAGATGCTA
Reverse GCCTCTCTTCACCAGATGGA
SREBP-2 Forward GTGGGTGACCGCCGTTCCTG
Reverse CTCGGCAGGCCTGAGCACAC
HMGCR Forward GGCCCAGTGGTGCGTCTTCC
Reverse TGGTCCCACCACCCACGGTT
LDLR Forward ACTCATGCAGCAGGAACG
Reverse GTCATTTTCACAGTCTAC
GAPDH Forward AACTTTGGCATTGTGGAAGG
Reverse ACACATTGGGGGTAGGAACA
For human hepatoma HepG2 cells
SREBP-1c Forward GACAGCCCAGTCTTTGAGGA
Reverse GAGAAGCACCAAGGAGACGA
FAS Forward CTCCGCCGAGTACAATGTCA
Reverse CCACTTGATGAGTGGGGAGA
ACC Forward GCATAACCAGGTGGAGTCCA
Reverse GTCAGGGTTGGTGATGCTGA
SREBP-2 Forward GGTCATTCACCCAGGTCACA
Reverse TACCTGGGAGGATGTCACCA
HMGCR forward CCAGCCAAGGTTGTCAGAGA
Reverse GTAGTAGGTTGGTCCCACCA
LDLR Forward GAACTGGTGTGAGAGGAC
Reverse CACTATCTCCACCGTGGT
GAPDH Forward CTCTGCTCCTCCTGTTCGAC
Reverse TTCCCGTTCTCAGCCTTGAC
SREBP-1c/2, sterol regulatory element-binding protein-1c/2; FAS, fatty acid synthase;
reductase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.thickness and expressed as arbitrary units (pixels). The results are
presented as the mean lesion size ± SEM for each group.2.8. Total RNA extraction and reverse transcription polymerase
chain reaction (RT-PCR)
Total RNAwas isolated frommouse livers and HepG2 cells using
TRIzol reagent in accordance with the manufacturer's instructions.
First-strand cDNA was reverse transcribed from 2 mg total RNA
using reverse transcriptase (Takara Bio) with random hexamers.
PCR was performed with speciﬁc primers using Taq polymerase
(Takara Bio) in a thermal cycler (MJ Research, Waltham, MA, USA).
The sequences of the primers are shown in Table 1. PCR productsAnnealing temp. (C) Cycle no. Product size (bp)
65 33 560
65 30 775
58 30 319
65 30 599
65 30 658
55 35 221
57 30 223
58 30 315
60 30 319
60 33 319
60 30 314
60 30 301
55 304
60 30 270
ACC, acetyl-CoA carboxylase; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A
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after GelRed staining (Biotium Inc.). Quantiﬁcation of band in-
tensities was performed using Image Master Total Lab (Amersham
Pharmacia, Piscataway, NJ, USA). GAPDH was used as an endoge-
nous control for normalization. Data are expressed relative to un-
treated controls.2.9. Western blot analysis
Liver tissue was homogenized in RIPA buffer containing
protease and phosphatase inhibitor cocktail (SigmaeAldrich).
Protein samples (50 mg) were separated on a 7.5% poly-
acrylamide gel (SREBP-2, HMGCR) and transferred onto PVDF
membranes. After blocking nonspeciﬁc binding using 5% skim
milk for 1 h, the blots were incubated with a primary antibody
against SREBP-2 (1:250; Santa Cruz), HMGCR (1:500; Abcam),
LDLR (1:200; Santa Cruz) or b-actin (1:2000; SigmaeAldrich) at
4 C overnight, followed by appropriate secondary antibodies
conjugated to horseradish peroxidase (HRP; 1:2000e5000;
Santa Cruz) for 1 h. The signals were detected using ECL or ECL
plus reagents (Thermo Fisher Scientiﬁc Inc., Waltham, MA,
USA). b-actin was used as a loading control. The band intensity
was quantiﬁed using image-analysis software (Image Master
Total Lab; Amersham Pharmacia Biotech) and normalized to
that of b-actin. Data are expressed relative to untreated
controls.2.10. Statistical analysis
The data are presented as the means ± SEM. The experimental
data were analyzed using one-way ANOVA with Tukey's post hoc
test (SPSS 13.0; SPSS, Chicago, IL, USA). In all analyses, P < 0.05
represented statistical signiﬁcance.Fig. 2. Effects of fucoidan on serum lipids and atherogenic index in P407-induced hyper
kg) administration in mice. The serum samples were collected 24 h after administration of P4
high-density lipoprotein cholesterol (HDL-c) levels and the atherogenic index (AI) were evalu
saline; P407, P407-induced hyperlipidemic mice treated with saline; FU10, P407-induced hy
mice treated with 30 mg/kg fucoidan; FU50, P407-induced hyperlipidemic mice treated wi
atorvastatin. *P < 0.05, **P < 0.01, and ***P < 0.001 determined by one-way ANOVA compa3. Results
3.1. Fucoidan improves serum lipid parameters in P407-induced
hyperlipidemic mice
To verify whether fucoidan has lipid-lowering activity, acute
hyperlipidemia was elicited by a single intraperitoneal injection of
P407 into mice, and the antihyperlipidemic effect of intraperito-
neally administered fucoidan was investigated in this mouse
model. The serum lipid levels were measured 24 h after P407 in-
jection (Fig. 2). Atorvastatin, an inhibitor of HMGCR with beneﬁcial
effects, was used as a positive control. Before fucoidan treatment, a
single injection of P407 resulted in highly signiﬁcant increases in
serum TC, TG, and LDL-c levels in the mice by 216%, 1522%, and
1409%, respectively, and amarked decrease in serumHDL-c level by
51% compared with those in the NOR group. Serum TC, TG, and LDL-
c concentrations were lower in the fucoidan-treated mice by 31%,
41%, and 32%, respectively, compared with those in P407-induced
hyperlipidemic mice in a dose-dependent manner. On the other
hand, fucoidan signiﬁcantly increased the HDL-c level by 92% in a
dose-dependent manner. To support the lipid-lowering potential of
fucoidan, the AI, a possible indicator of predisposition to heart
disease, was also evaluated. Consistent with the above observa-
tions, fucoidan treatment signiﬁcantly decreased the AI value in a
dose-dependent manner in comparison with that in the non-
treated P407 group. The restorative effect of fucoidan and the AI
in the FCN50 group (50 mg/kg) were compatible with those in the
STA group (10 mg/kg atorvastatin).3.2. Fucoidan regulates mRNA expression of genes involved in
lipogenesis regulation in HepG2 cells
Elevated fatty acid synthesis in the liver and subsequent TG
synthesis predominantly contribute to the accumulation of lipids inlipidemic mice. Fucoidan was injected intraperitoneally 2 h after acute P407 (250 mg/
07. Total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-c),
ated. Data are presented as means ± SEM (n ¼ 6 each). NOR, normal mice treated with
perlipidemic mice treated with 10 mg/kg fucoidan; FU30, P407-induced hyperlipidemic
th 50 mg/kg fucoidan; STA, P407-induced hyperlipidemic mice treated with 10 mg/kg
red with the P407 group.
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expression levels of genes involved in control of lipogenesis (FAS
and ACC) were analyzed in human hepatoma HepG2 cells using RT-
PCR. Compared with untreated HepG2 cells, fucoidan treatment
signiﬁcantly decreased the levels of FAS and ACC mRNA by 87% and
89%, respectively, in a concentration-dependent manner (Fig. 3A).
Fatty acid synthesis mediated by ACC and FAS is transcriptionally
regulated by SREBP-1c (7). To determine whether SREBP-1c is
involved in the suppressive effect of fucoidan on lipogenesis, the
mRNA level of the SREBP-1c gene itself was examined in fucoidan-
treated HepG2 cells. However, in contrast to our expectations,
fucoidan did not signiﬁcantly reduce the SREBP-1c mRNA level in
fucoidan-treated cells (Fig. 3B).
To examine whether the inhibitory effects of fucoidan on mRNA
levels of SREBP-1c and its target genes in HepG2 cells were due to
cytotoxicity by fucoidan itself, the cell viability was also examined
by WST assay 24 h after fucoidan treatment. The concentrations ofFig. 3. Effects of fucoidan on the mRNA levels of genes involved in fatty acid metabolism
in MEM containing 10% lipoprotein-deﬁcient serum (LPDS) for 24 h. The mRNA levels of lipo
internal control. Results were normalized to GAPDH expression and expressed as percentag
experiments performed in triplicate. *P < 0.05, **P < 0.01, and ***P < 0.001 determined by
Fig. 4. Effects of fucoidan on mRNA levels of genes involved in cholesterol metabolism i
in MEM medium containing 10% lipoprotein-deﬁcient serum (LPDS) for 24 h. The mRNA ex
Western blot, respectively. Results were normalized to GAPDH or b-actin expression and exp
three independent experiments performed in triplicate. **P < 0.01 and ***P < 0.001 determfucoidan used in this study (up to 100 mg/ml) did not lead to any
signiﬁcant cytotoxicity (data not shown).
3.3. Fucoidan regulates expression of genes involved in cholesterol
metabolism in HepG2 cells
Next, we investigated the effects of fucoidan on the expression
of genes involved in cholesterol metabolism (HMGCR and LDLR) in
HepG2 cells. RT-PCR analysis revealed that both HMGCR and LDLR
mRNA levels were signiﬁcantly reduced by 86% and 55%, respec-
tively, in HepG2 cells following treatment with fucoidan (Fig. 4A).
To determine the molecular mechanism underlying the transcrip-
tional inhibition of the HMGCR and LDLR genes by fucoidan, the
effects of fucoidan on SREBP-2 mRNA expression were also evalu-
ated by RT-PCR, because SREBP-2 plays a critical role in hepatic
cholesterol homeostasis by regulating lipogenic genes, such as
HMGCR and LDLR. As shown in Fig. 4B, fucoidan treatment resultedin HepG2 cells. HepG2 cells were treated with the indicated concentrations of fucoidan
genic genes (A) and of SREBP-1c (B) were analyzed by RT-PCR. GAPDH was used as an
es of the untreated control. Each bar represents the mean ± SEM of three independent
one-way ANOVA compared to the untreated controls.
n HepG2 cells. HepG2 cells were treated with the indicated concentrations of fucoidan
pression levels of lipogenic genes (A) and of SREBP-2 (B) were analyzed by RT-PCR and
ressed as percentages of the untreated control. Each bar represents the mean ± SEM of
ined by one-way ANOVA compared with the untreated controls.
J. Park et al. / Journal of Pharmacological Sciences 131 (2016) 84e92 89in a marked decrease in the level of SREBP-2 mRNA expression in a
concentration-dependent manner.
3.4. Fucoidan regulates the expression of genes controlling fatty
acid metabolism in P407-induced hyperlipidemic mice
The liver is one of the most important organs for maintaining
the homeostasis of fatty acids and cholesterol in the body. To
further conﬁrm the in vitro effects of fucoidan on SREBP-1c and its
target genes, changes in the mRNA expression of genes involved in
the control of fatty acid metabolism by fucoidan treatment in the
liver of P407-induced hyperlipidemic mice were determined by
RT-PCR. Acute administration of P407 to the mice increased the
hepatic expression of FAS and ACC mRNA by 30% and 60%,
respectively, in comparison with the NOR group. However, as ex-
pected, fucoidan inhibited FAS by 70% and ACC by 36% in theFig. 5. Effects of fucoidan on mRNA levels of genes involved in fatty acid metabolism
toneally 2 h after acute P407 (250 mg/kg) administration. Liver samples were collected 24
SREPB-1c (B) were determined by RT-PCR and normalized to that of GAPDH as an internal co
treated with saline; FU10, P407-induced hyperlipidemic mice treated with 10 mg/kg fucoid
P407-induced hyperlipidemia-c mice treated with 50 mg/kg fucoidan; STA, P407-induced
***P < 0.001 determined by one-way ANOVA compared with the P407 group.
Fig. 6. Effects of fucoidan on the expression of genes involved in cholesterol metaboli
peritoneally 2 h after acute P407 (250 mg/kg) administration. Liver samples were collected 2
and SREPB-2 (B) were analyzed by RT-PCR and normalized to that of GAPDH as an internal c
treated with saline; FU10, P407-induced hyperlipidemic mice treated with 10 mg/kg fucoid
P407-induced hyperlipidemic mice treated with 50 mg/kg fucoidan; STA, P407-induced
***P < 0.001 determined by one-way ANOVA compared with the P407 group.mouse liver in a dose-dependent manner in comparison with the
P407 group, as also observed in HepG2 cells (Fig. 5A). P407
administration did not alter the SREBP-1c mRNA level. Although
fucoidan caused a slight decrease in the level of SREBP-1c mRNA,
the change was not signiﬁcant (Fig. 5B). These results were also
consistent with the ﬁndings in hyperlipidemic rats treated with
simvastatin (STA group).
3.5. Fucoidan decreases the mRNA and protein levels of genes
controlling cholesterol metabolism in the livers of P407-induced
hyperlipidemic mice
We also analyzed the effects of fucoidan on the expression of
SREBP-2 and its target genes in the livers of P407-induced hyper-
lipidemic mice to conﬁrm the in vitro effects of fucoidan on the
expression of cholesterogenic genes. As shown in Fig. 6A, the acutein the liver of P407-induced hyperlipidemic mice. Fucoidan was injected intraperi-
h after administration of P407. The mRNA expression levels of lipogenic genes (A) and
ntrol. NOR, normal mice treated with saline; P407, P407-induced hyperlipidemic mice
an; FU30, P407-induced hyperlipidemic mice treated with 30 mg/kg fucoidan; FU50,
hyperlipidemic mice treated with 10 mg/kg atorvastatin. *P < 0.05, **P < 0.01, and
sm in the liver of P407-induced hyperlipidemic mice. Fucoidan was injected intra-
4 h after administration of P407. The relative mRNA levels of cholesterogenic genes (A)
ontrol. NOR, normal mice treated with saline; P407, P407-induced hyperlipidemic mice
an; FU30, P407-induced hyperlipidemic mice treated with 30 mg/kg fucoidan; FU50,
hyperlipidemic mice treated with 10 mg/kg atorvastatin. *P < 0.05, **P < 0.01, and
J. Park et al. / Journal of Pharmacological Sciences 131 (2016) 84e9290administration of P407 resulted in an increase in hepatic expression
of HMGCR mRNA by 294% but a decrease in that of LDLR mRNA by
60% in comparison with the NOR group. Fucoidan treatment
signiﬁcantly lowered HMGCR mRNA expression by 51% in a dose-
dependent manner in comparison with the P407 group, while it
markedly increased the level of LDLRmRNA expression by 160% also
in a dose-dependent manner. Similar to their mRNA levels,
fucoidan-treated mice showed a markedly decreased HMGCR pro-
tein level and a signiﬁcantly increased LDLR protein level (Fig. 7A).
The acute administration of P407 resulted in an increase in hepatic
expression of SREBP-2 mRNA by 221% in comparison with the NOR
group. Fucoidan treatment signiﬁcantly lowered SREBP-2 mRNA
expression by 60% in a dose-dependent manner in comparisonwith
the P407 group (Fig. 6B). Since the transcription factor activity of
SREBP is largely regulated by the maturation process of precursorFig. 7. Effects of fucoidan on the expression of proteins involved in cholesterol met
intraperitoneally 2 h after acute P407 (250 mg/kg) administration. Liver samples were colle
and mSREPB-2 (B) were analyzed byWestern blot analysis. NOR, normal mice treated with sa
hyperlipidemic mice treated with 10 mg/kg fucoidan; FU30, P407-induced hyperlipidemic m
with 50 mg/kg fucoidan; STA, P407-induced hyperlipidemic mice treated with 10 mg/kg
compared with the P407 group.
Fig. 8. Effects of fucoidan on P407-induced atherogenesis in mice. C57BL/6 mice were inje
atorvastatin were only administered intraperitoneally 2 h after every P407 injection. Aortas
stained aortas (A) were obtained from untreated normal mice (NOR), P407-induced ather
(FU50), and P407-induced atherogenic mice treated with 10 mg/kg atorvastatin (STA). Origin
means ± SEM (n ¼ 6 each). *P < 0.05, **P < 0.01, and ***P < 0.001 determined by one-wayproteins (22), Western blotting was performed to determine the
protein level of mature SREBP-2 (mSREBP-2). The changes in SREBP-
2 protein level paralleled those of the mRNA level (Fig. 7B).
3.6. Fucoidan decreases atherosclerosis development in P407-
induced atherogenic mice
Elevated fatty acid synthesis in the liver and subsequent TG
synthesis predominantly contributes to the accumulation of
cholesterol within the intima of arterial blood vessels, which is a
prominent feature of atherosclerosis. The effects of fucoidan on the
formation of atherosclerotic lesions were explored in the P407-
induced atherogenic mouse model. As indicated in Fig. 8A, the
aortas of P407-induced atherogenic mice showed pathological le-
sions that were thickened. The arterial thickening (atheroscleroticabolism in the liver of P407-induced hyperlipidemic mice. Fucoidan was injected
cted 24 h after administration of P407. The protein levels of cholesterogenic genes (A)
line; P407, P407-induced hyperlipidemic mice treated with saline; FU10, P407-induced
ice treated with 30 mg/kg fucoidan; FU50, P407-induced hyperlipidemic mice treated
atorvastatin. *P < 0.05, **P < 0.01, and ***P < 0.001 determined by one-way ANOVA
cted intraperitoneally with 400 mg/kg P407 every third day for 16 weeks. Fucoidan and
were collected 24 h following the last P407 injection. Representative images of HeE-
ogenic mice (P407), P407-induced atherogenic mice treated with 50 mg/kg fucoidan
al magniﬁcation 400 (inset, 40). Intima-media thicknesses (B) are expressed as the
ANOVA compared with the P407 group.
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tunica intima of the aorta in the fucoidan- or atorvastatin-treated
atherogenic mice was signiﬁcantly lower than that in untreated
P407-induced atherogenic mice (Fig. 8A and B). The above data
indicate that fucoidan effectively inhibits atherosclerosis lesion
formation.
4. Discussion
Here, we demonstrated that fucoidan improves abnormal serum
lipid levels and reduces atherogenesis in P407-induced hyper-
lipidemic mice. The molecular mechanism underlying this effect
may be related to inhibition of hepatic expression of lipogenic
enzymes (FAS and ACC), in particular, cholesterogenic genes
(HMGCR and LDLR) by SREBP-2.
In the present study, P407 (also known as Pluronic® F-127) was
used to induce the development of acute hyperlipidemia and
chronic atherosclerosis in mice. As a nongenetically altered,
nondiet-induced mouse model of hyperlipidemia and atheroscle-
rosis, these mice have many advantages in that they have much
more controllable hyperlipidemia levels and atherosclerotic lesions
than the classic high-fat diet-induced mouse model, being closer to
the human condition than knock-out mouse models and less toxic
than other chemically induced mouse models using biphenyls,
nicotine, isotretinoin, carbon disulﬁde, etc. (23). Since it has a
structure of synthetic block copolymers consisting of alternating
units of hydrophobic propylene oxide and hydrophilic ethylene
oxide, P407 may physically inhibit the passage of small-sized li-
poproteins (<100e200 nm in diameter) from the bloodstream into
the liver sinusoidal endothelial cells, prior to receptor-mediated
uptake, which results in increased levels of lipoproteins in the
blood and consequently causes massive hyperlipidemia and
atherosclerosis in rodent models (24).
The beneﬁcial effect of fucoidan on lipid metabolism was
demonstrated by signiﬁcant decreases in TC, TG, and LDL-c levels
and an increase in HDL-c. These results conﬁrmed those of several
previous studies indicating that fucoidan plays a role in lowering
serum lipid levels in hyperlipidemia or helping to prevent athero-
sclerosis (16,17,25). These beneﬁcial effects of fucoidan seem to be
mediated by inducing LPL secretion from adipocytes (26) or
improving an antioxidant defense system (17). In addition, we
attempted to elucidate another mechanism by which fucoidan
improves lipid metabolism in hyperlipidemic mice by investigating
the effects of fucoidan on the expression of genes involved in fatty
acid biosynthesis and cholesterol metabolism.
In human hepatoma HepG2 cells and liver tissues, fucoidan
treatment resulted in marked decreases in the expression of
genes affecting fatty acid synthesis, e.g., FAS and ACC, a signiﬁcant
reduction in HMGCR, the rate-limiting enzyme in the biosyn-
thesis of cholesterol, and a marked increase in LDLR, a hepatic
cholesterol uptake-related protein. The regulatory effect of
fucoidan on the expression of these genes in the liver is likely to
be responsible for its lipid-lowering activities in the blood of
hyperlipidemic mice.
SREBPs are important transcription factors that regulate the
biosynthesis of fatty acids and cholesterol (27); SREBP-1c enhances
transcription of genes involved in fatty acid biosynthesis (28),
whereas SREBP-2 preferentially regulates genes involved in
cholesterol biosynthesis (8). The patterns of mature SREBP-1c
expression and its activity were closely associated with the
changes in mRNA levels of the lipogenic genes, whereas the
expression pattern of mature SREBP-2 protein paralleled the
changes in mRNA levels of genes related to cholesterol metabolism
(29). However, although fucoidan signiﬁcantly reduced mRNA
levels of both lipogenic enzymes of FAS and ACC in vivo as well asin vitro in the present study, the expression of SREBP-1c mRNA
seemed to be unaffected. SREBP-1c is a lipogenic transcriptional
factor that regulates the transcription of lipogenic enzymes (7).
These observations suggest that fucoidan may decrease hepatic
lipogenesis through the SREBP-1c-dependent mechanism. How-
ever, contrary to our expectations, fucoidan did not affect themRNA
level of SREBP-1c, suggesting that inhibition of these genes by
fucoidan may be SREBP-1c-independent. Although we focused on
the involvement of SREBP-2 on the beneﬁcial activity of fucoidan in
dyslipidemia, we cannot exclude the possibility that SREBP-1c is
involved in the fucoidan-elicited changes in expression of hepatic
lipogenic genes because the mRNA level of SREBP-1c does not al-
ways correspond with the level of the mature SREBP-1c protein
located in the nucleus (30,31). Accordingly, it is necessary to
determine the protein level of themature form of SREBP-1c in order
to verify the role of this transcription factor in the inhibitory effect
of fucoidan on expression of hepatic lipogenic genes.
Acute administration of P407 to the mice increased the levels of
mature SREBP-2 mRNA and protein as well as the expression of
HMGCRmRNA and protein, but it decreased the expression of LDLR
mRNA and protein at the same time in the liver. Although this was
explained by the signiﬁcant reductions of serum TC and LDL-c
levels, associated with the inhibition of HMGCR and the elevation
of LDLR through the inhibition of SREBP-2, it was also notable that
the expression of LDLR was attenuated in the liver of P407-induced
hyperlipidemic mice because activation of SRPBP-2 generally leads
to transcriptional activation of LDLR. However, hepatic LDLRs may
also be regulated post-transcriptionally by proprotein convertase
subtilisin/kexin type 9a (PCSK9). As SREBP-2 also activates Pcsk9 in
the liver, the increase in PCSK9 expression through SREBP-2 acti-
vation can attenuate hepatic LDLR protein expression and subse-
quently reduce serum cholesterol levels (32). Therefore, we could
not exclude the possibility that fucoidan can elevate LDLR through
the PCSK9-mediated pathway.
In addition to its hypolipidemic effect, the protective effect of
fucoidan against atherogenesis was also observed in this study.
Increased levels of TC, TG, and LDL-c and decreased levels of HDL-c
are associated with an increased incidence of cardiovascular dis-
ease in the general population. AI based on serum lipid proﬁle is a
reliable indicator of predisposition to cardiovascular disease. In
addition, a low level of HDL-c is also considered an important risk
factor for cardiovascular diseases due to the strong association
between lower HDL-c level and the incidence of coronary heart
disease (33,34). In this study, fucoidan signiﬁcantly reduced AI and
markedly increased serum HDL-c level as compared with P407-
induced hyperlipidemic mice. These effects may partly explain its
beneﬁcial protective effect against the development of athero-
sclerosis, suggesting that fucoidan may confer signiﬁcant protec-
tion against cardiovascular disease and mortality. The other
evidence, however, shows fucoidan also exerts anti-inﬂammatory
and antioxidative effects (10), which may contribute to the atten-
uation of atherosclerosis as well as hypolipidemic effect. It can also
raise the possibility that fucoidan cannot only improve serum lipid
proﬁles, but protect against the development of atherosclerosis via
its anti-inﬂammatory and antioxidative effects.
Taken together, the results of the present study indicated that
fucoidan inhibits hyperlipidemia and aortic lesion development in
P407-induced hyperlipidemic mice and may affect hepatic lipid
metabolism. To our knowledge, this is the ﬁrst study to reveal a
novel mechanism of action for fucoidan in which it lowers serum
lipid levels by suppressing SREBP-2. In conclusion, the hypolipi-
demic effects of fucoidan could account for decreased HMGCR via
suppression of SREBP-2. Therefore, fucoidan may be beneﬁcial
against hyperlipidemia and atherosclerosis and, therefore, be car-
dioprotective and reduce the risk of CHD.
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